Pulsenmore Ltd.
Pulsenmore Ltd. develops portable, home-use ultrasound solutions that connect patients with healthcare providers remotely. Its products are designed for non-invasive self-scanning and telehealth-supported imaging, with an initial focus on maternal health and women’s care, and development work extending into other clinical monitoring applications.
Business
Share of revenuePulsenmore ES and related products used by expectant mothers for remote prenatal imaging and telehealth guidance.
Pulsenmore FC for ovarian follicle and endometrial self-examination in fertility care.
Next-generation portable ultrasound products such as Pulsenmore MC under development for new medical uses.
Regulatory, marketing, and sales activities supporting adoption of the company’s ultrasound platforms.
Product supply and study support for clinical research and feasibility work in additional territories.
Customers
The company sells into healthcare workflows rather than consumer retail, so its buyers include providers, telehealth-enabled care programs, and fertility practices that want to extend imaging beyond the clinic. End users are patients, especially expectant mothers and women in fertility care, who perform scans at home under medical supervision. As new indications develop, the customer base can also include clinical research institutions and health systems evaluating remote monitoring tools.
Buy home-use prenatal ultrasound workflows to extend monitoring beyond the clinic and improve continuity of care.
Use Pulsenmore ES for self-scans and telehealth-guided prenatal imaging at home.
Use Pulsenmore FC for ovarian follicle and endometrial self-examination in fertility treatment.
Evaluate the company’s devices in studies and feasibility trials for new medical applications.
Adopt connected imaging tools that support remote monitoring and reduce in-clinic dependence.
Strategy
Pulsenmore’s strategy centers on making ultrasound available at home while preserving clinician oversight through telemedicine connectivity. It is expanding from prenatal care into fertility and other remote monitoring uses, while building evidence, regulatory approvals, and market access for each new indication. The company’s competitive position depends on turning a specialized medical workflow into a repeatable platform that can be adopted by providers across countries.
Prenatal care is the company’s most established use case and the anchor for broader adoption.
Fertility monitoring broadens the addressable market and uses the same remote-imaging platform.
Additional uses in pulmonary and cardiac monitoring can increase platform utility over time.
Medical device adoption depends on regulatory clearance, clinician acceptance, and clinical validation.
Geography
Pulsenmore is headquartered in Israel, with its principal office in Omer, and its commercial footprint extends across multiple approved markets. The Pulsenmore ES is approved in the United States, Europe, Switzerland, Australia, Brazil, Colombia, and Israel, while Pulsenmore FC is approved in Israel and used in other territories for research. This makes regulatory approvals and market access central to where the company can sell and deploy its products.
Risks
The business depends on successful regulatory approvals, clinical evidence, and physician adoption for each product and country, so commercialization risk is concentrated in execution rather than manufacturing scale. As a medical device company focused on new usage models, it also faces development risk, reimbursement uncertainty, and the possibility that telehealth-linked home scanning proves harder to standardize than clinic-based imaging. International expansion adds country-specific approval, market-access, and operational complexity.
- Regulatory approval riskImpact: HighLikelihood: Medium
Each product and market requires device clearance or approval before sale.
Exposure - Clinical adoption riskImpact: HighLikelihood: Medium
Providers and patients must trust remote self-scanning and telehealth workflows.
Exposure: Prenatal care and fertility workflows
- Reimbursement and market-access riskImpact: HighLikelihood: Medium
Commercial traction can be limited if payers and providers do not support home imaging workflows.
Exposure: Healthcare systems and telehealth channels
- Product development riskImpact: MediumLikelihood: High
New indications such as Pulsenmore MC remain in early-stage development.
Exposure: Pulsenmore MC and future pipeline products
- International execution riskImpact: MediumLikelihood: High
Operating across multiple countries creates differing standards, approvals, and support requirements.
Exposure
Accounting
Judgemental itemsThe company states that significant judgments affect reported assets, liabilities, income, and expenses.
Impact: Can change expense timing and balance-sheet values
New issued warrants and pre-funded warrants are classified as financial liabilities.
Impact: May create mark-to-market income statement volatility
Interim financials are reported in NIS and translated into USD for convenience.
Impact: Creates FX-related comparability issues across periods
Clinical feasibility trials and product development require judgment on cost treatment.
Impact: Affects operating expense recognition and asset values
Similar listed companies
Publicly listed companies with a comparable business focus.
Butterfly Network, Inc.
BFLY · X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Pulse Biosciences, Inc
PLSE · Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems.
Femasys Inc
FEMY · Surgical & Medical Instruments & Apparatus
RadNet, Inc.
RDNT · Services-Medical Laboratories
Masimo Corp
Electromedical & Electrotherapeutic Apparatus
Masimo Corp develops and markets noninvasive patient monitoring technologies, hospital automation and connectivity solutions, and remote monitoring devices for healthcare settings.
Escalon Medical Corp
ESMC · Electromedical & Electrotherapeutic Apparatus
Last updated: 28/09/2026